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PET-CT；模型三，PET-CT 和 CT 联合使用；模型四，单纯使用 PET-CT。2、在 CNKI




及增量成本效果比 ( Incremental Cost-effectiveness Ratio，ICER)，通过比较 ICER，
评价 PET-CT 在非小细胞肺癌术前 N 分期中的应用价值。4、针对影响成本效果分
析结果的因素进行单因素灵敏性分析。5、所有计算均通过 R 软件编程实现。 
结果： 
1、检索数据库获得决策树参数、期望寿命和化疗费用数据相关文献 59 篇,








与 CT 相比，PET-CT 的灵敏度、特异度均较高，尤其在灵敏度方面优势明显。
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Abstract 
Objective: To evaluate the cost-effectiveness and significance of PET-CT in the 
mediastinal Lymph Node Staging of Non-Small Cell Cancer (NSCLC). Methods: 1. 
Simulating clinical practice guidelines of NSCLC, four decision tree models were 
established, that is CT only（Model 1）, PET-CT for negative CT (Model 2), PET-CT 
for all with CT (Model 3), and PET-CT only (Model 4). 2. Retrievaling and acquiring 
the related decision tree parameters from CNKI database and ISI Web of Science 
database, and the cost data was obtained from the medical service fee standards of the 
domestic Official Price Bureau Website. 3. Using Model 1 as the baseline strategy, 
examination and treatment charge as cost, life expectancy as the effectiveness, cost， 
life expectancy and ICER(Incremental Cost-effectiveness Ratio) of each strategy were 
calculated. 4. Sensitivity analysis was performed to determine the effects of changing 
variables on the related parameters. 5. All computational process was performed by 
Software R programming. Results: 1.  59 papers on the related decision tree 
parameters were gain. The number of NSCLC patients was 4486, and the number of 
Lymph Nodes was 2131.  2. Compared to Model one, the proportion of the correct 
treatment of Model two, Model three and Model four were more. The proportion of 
mortality of Model two was more than Model two, Model three and Model four. But 
the proportion of the wrong treatment of Model one was more than Model two, Model 
three and Model four. 3. The expected cost of Model 2 was reduced, and the expected 
cost of Model 3， 4 were both increased. Model three was shown to be a 
cost-effectiveness alternative, with life expectancy increased by 0.081 years.  4. 
Sensitivity analyses showed the robustness of the results. Conclusion: Compared to 
CT examination, sensitivity and specificity of PET-CT examination were all higher. 
The introduction of PET-CT into the Mediastinal Lymph Node Staging of Non-Small 
Cell Cancer is potentially cost-effective, with life expectancy increased. 
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新发病例将达 2000 万，现患癌症病例将达 3000 万，死亡将近 1200 万，届时癌
症将成为新世纪人类第一杀手[1]。肺癌是对人类健康和生命危害 严重的恶性肿
瘤，肺癌发病率和死亡率均居癌症的首位。在全球，2000 年，肺癌新发病例 123.9
万例，死亡 110 万例[2]；2008 年，全球肺癌新发病例 162.5 万，死亡 137.8 万例
[3]。在我国，肺癌的发病率和死亡率也不断攀升。20 世纪 70 到 90 年代，我国肺
癌死亡率从 5.47/10 万上升到 17.27/10 万，提高 11.80/10 万；男性肺癌死亡率
从 7.17/10 万上升到 23.41/10 万，提高 16.24/10 万；女性肺癌死亡率从 3.69/10






仍是根治 NSCLC 的主要手段，而术前纵隔淋巴结分期（N 分期），对合理选择治
疗方式有着重要意义。 
非小细胞肺癌 N 分期方法主要包括：1、无创分期：即影像学检查，如 CT， 
PET-CT 等；2、有创分期：即病理学检查，如纵隔镜检查，胸腔镜检查等。其中
纵隔镜检查是 N 分期诊断的金标准。CT 检查是目前 常用的无创 N 分期方法，
但 CT 检查容易出现假阳性和假阴性，而 PET-CT 具有较好的灵敏度和特异度，在






















































 本模型仅利用 CT 进行术前 N 分期，当 CT 结果阳性时，部分患者行纵隔镜活
检，其他患者直接进行化疗；活检阳性患者不进行手术，进行化疗治疗，活检阴
性者行手术治疗。当 CT 阴性时，进行手术治疗。具体决策路径见图 2-1。 
2.1.2 模型二 





 本模型中，对患者先行 CT 检查，不同于模型二的是，无论 CT 检查结果为阳




















 本模型不同于模型二、模型三的是，仅利用 PET-CT 进行术前 N 分期，不行
CT 检查。当 PET-CT 阳性时，部分患者行纵隔镜活检，其他患者直接进行化疗治
疗；活检阳性患者不能进行手术，进行化疗治疗，活检阴性者直接行手术治疗。
当 PET-CT 结果阴性时，患者直接进行手术治疗。具体决策路径见图 2-4。 
 
 
图 2-1  单纯使用 CT 决策路径图 
（ ，表示决策点， ，表示机会点， 表示决策终点，下图同） 
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